Table 2.
FXa inhibition and IC50 values of novel compounds 8a–t.
| Entry | %Inhibition FXa 1 | IC50 (μM) |
| 8a | 68 | 41.2 ± 1.2 |
| 8b | 24 | - |
| 8c | 17 | - |
| 8d | 33 | - |
| 8e | 17 | - |
| 8f | 44 | - |
| 8g | 36 | - |
| 8h | 25 | - |
| 8i | 29 | - |
| 8j | 23 | - |
| 8k | 59 | 76.2 ± 16.9 |
| 8l | 50 | 52.9 ± 5.5 |
| 8m | 29 | - |
| 8n | 22 | - |
| 8o | 37 | - |
| 8p | 65 | 17.2 ± 0.8 |
| 8q | 21 | - |
| 8r | 27 | - |
| 8s | 37 | - |
| 8t | 31 | - |
| Gabexate mesylate | 93 | 0.34 ± 0.10 |
| Apixaban | 97 | 0.0028 ± 0.0001 |
| Rivaroxaban | 94 | 0.0007 ± 0.0001 |
1 Inhibition percentage at 100 μM; standard inhibitor gabexate mesylate. Control samples: apixaban and rivaroxaban.